[
    [
        {
            "time": "",
            "original_text": "健帆生物(300529.SZ)发布半年报 净利润升45.63%至3.06亿元",
            "features": {
                "keywords": [
                    "健帆生物",
                    "半年报",
                    "净利润",
                    "增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529.SZ)发布半年报 净利润升45.63%至3.06亿元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "健帆生物：上半年净利润同比增45.63%",
            "features": {
                "keywords": [
                    "健帆生物",
                    "上半年",
                    "净利润",
                    "同比增长"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物：上半年净利润同比增45.63%",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "健帆生物：节余募集资金永久性补充流动资金",
            "features": {
                "keywords": [
                    "健帆生物",
                    "募集资金",
                    "补充流动资金"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "健帆生物：节余募集资金永久性补充流动资金",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【广证恒生医药】-健帆生物（300529）-点评报告-灌流器在肾病和肝病领域加速渗透，2019年H1扣非后业绩54%高增长",
            "features": {
                "keywords": [
                    "广证恒生医药",
                    "健帆生物",
                    "灌流器",
                    "肾病",
                    "肝病",
                    "高增长"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【广证恒生医药】-健帆生物（300529）-点评报告-灌流器在肾病和肝病领域加速渗透，2019年H1扣非后业绩54%高增长",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]